pharmaphorum

JANUARY 30, 2022

The debut was the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014, and followed a £195 million fundraising round for Oxford Nanopore in May. The Oxford University spin-out rose to prominence for commercialising the technology platform behind the Oxford/AstraZeneca COVID-19 vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

JULY 14, 2021

In 2014, six years after the global financial crisis forced the world’s biggest financial institutions into some serious navel gazing, the CEO of a major international bank was despairing: “We’ve put in place a best-in-class compliance system, but we can’t stop our people acting badly.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Communication Vaccines 105

Pharmaceutical Technology

SEPTEMBER 5, 2022

Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We We want to be a sustainably growing company. billion in development.

FDA 114

FDA Vaccines 114

European Pharmaceutical Review

JUNE 27, 2023

About the interviewees Hervé Affagard is the CEO and co-founder of MaaT Pharma, which was established in late 2014. He has also held the role of Vice President and Therapeutic Area Head, Vaccine Clinical Research at Merck & Co. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry.

Chemotherapy 105

Chemotherapy Immunization FDA Vaccines 105

pharmaphorum

SEPTEMBER 18, 2020

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2 In April 2008, AstraZeneca also reached an agreement with Ranbaxy, an Indian generic drugmaker, allowing it to produce a generic version of Nexium starting in May 2014. Pfizer makes its move.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 116

ISPE

MAY 9, 2023

Jaguar Gene Therapy is building a $125 million facility in RTP to manufacture adeno-associated virus (AAV)-based gene therapies, Beam Therapeutics is constructing an $83 million plant to develop precision medicines, and IQVIA, a CRO, opened an innovation lab in the park in 2021, focusing on bioanalytics, vaccines, biomarkers, and genomics.

Vaccines 94

Vaccines Pharmaceutical Companies Pharmaceutical Companies Medical Schools 94

PQA

NOVEMBER 16, 2023

Here are the PQA Executive Fellowship alumni and where they are today: Laurin Dixon, PharmD, Lead Executive, Medicare Products, Arkansas Blue Cross and Blue Shield (2013-2014 Executive Fellow) Maria Scarlatos Eid, PharmD, CPHQ, Global Professional Relations & Independent Medical Education, Vaccines, Merck (2014-2015 Executive Fellow) Hannah (..)

Vaccines 45

Vaccines 45

European Pharmaceutical Review

JANUARY 29, 2024

Repurposing of currently marketed products, eg, methotrexate, 20 was an important and effective strategy in combatting COVID-19, particularly in the early stages prior to effective vaccines being developed. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [OBSOLETE].

FDA 111

FDA Vaccines Compounding 111

European Pharmaceutical Review

MARCH 1, 2023

Nowhere is this more publicly evident than in the development, regulatory approval, and efficacious use of mRNA‑based vaccines for COVID-19. Beyond the high-profile COVID-19 vaccines, mRNA therapeutics are crucial in applications such as protein replacement therapies and regenerative medicine. 2014 Nov 20; 56(4), 506‑17.

Vaccines 111

Vaccines Packaging 111

pharmaphorum

OCTOBER 1, 2021

It also won a £113 million contract to provide rapid saliva-based COVID-19 testing services to the NHS, although that was ended early by the UK government in the summer as demand fell due to vaccinations.

Documentation 52

Documentation Vaccines 52

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. By 2016, Gilead already had competition for the HCV market, when MSD launched their product at €47,000 per treatment.

Insurance 52

Insurance Vaccines 52

Drug Topics

JULY 28, 2023

of women aged 18-59 in 2013-2014. According to the CDC, HPV is the most commonly sexually transmitted infection in the US, with a prevalence of 45.2% of men and 39.9%

Vaccines 247

Vaccines 247

Hospital Pharmacy Europe

AUGUST 21, 2023

And we should draw on our experience with Covid-19 to build the ‘toolbox’ for tackling antimicrobial resistance which will include work on diagnostics, surveillance, therapeutics and vaccines, the summary of consultation feedback said. The Government’s National Action Plan goal was to reduce prescribing by 15% by 2024 from a 2014 baseline.

Hospitals 52

Hospitals Vaccines 52

pharmaphorum

SEPTEMBER 9, 2021

COVID-19 also put global supply chains in the spotlight, as industry looked to remove obstacles and speed the delivery of material crucial to vaccine development processes. The aim is to work with start-up companies to generate ideas for digital therapeutics, patient support apps, and boosting research and development.

Patient Care 52

Patient Care Pharmaceutical Companies Pharmaceutical Companies Communication 52

Hospital Pharmacy Europe

NOVEMBER 23, 2023

The statements, which were adopted in 2014, express commonly agreed objectives which every European health system should aim for in the delivery of hospital pharmacy services. Looking forwards, the report concluded that further work is needed to support the development of hospital pharmacists in clinical service provision.

Hospitals 52

Hospitals Compounding Patient Care Vaccines 52

The FDA Law Blog

APRIL 7, 2025

Zenrelia comes with serious warnings, including a boxed warning against the use of Zenrelia during vaccination. CVM also objected to the truncation of other information about the timing of vaccines in these promotional materials. Zenrelia promotional materials also included claims about clinical data that the Agency found actionable.

Vaccines 64

Vaccines FDA Adverse Reactions 64

PharmaShots

FEBRUARY 21, 2023

Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

PharmaShots

MAY 23, 2023

Stock Exchange: TYO With focus areas extending to the discovery and development of biopharma products, AnGes is dedicated to developing genetic medicines and therapeutic vaccines for intractable or rare diseases. Approved Cell and Gene Therapy: Collategene Founded Year: 1999 Total Employees: ~140 Headquarters: Osaka, Japan Market Cap: $162.8M

FDA 58

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 58

ISPE

OCTOBER 26, 2022

ATMP facilities are different from conventional pharmaceutical facilities that process other traditional modalities, such as vaccines and monoclonal antibodies (mAbs), and often require heightened segregation and smaller footprints. Viral antigen vaccines. For example: Live vaccine manufacturing. Complete Data Gathering.

Vaccines 97

Vaccines Compounding Documentation FDA 97

STAT

NOVEMBER 10, 2022

 But he was ousted in 2014 after an embarrassingly public conflict with the Sanofi board. At Sanofi, Viehbacher was largely responsible for repositioning the staid drugmaker and for deepening its partnership with Regeneron Pharmaceuticals. But Continue to STAT+ to read the full story…

Vaccines 80

Vaccines 80

The FDA Law Blog

JANUARY 7, 2024

To better understand FDA’s approach in classifying postmarketing pregnancy studies as PMRs or PMCs, we reviewed all postmarketing requirements (PMRs) and postmarketing commitments (PMCs) related to maternal and fetal outcomes in FDA’s PMR/PMC database for drugs approved in the ten-year period from January 2014 through December 2023.

FDA 59

FDA Documentation Vaccines 59

pharmaphorum

MAY 20, 2022

She began her career in clinical research as a clinical trial assistant for Novartis Vaccines and Diagnostics in 2007 and continued to pursue her interest is vaccine research in 2014 when she joined GSK (formerly Novartis Vaccines). Sheena has a wealth of experience of managing and delivering clinical trials.

Hospitals 59

Hospitals Medical Records Vaccines 59

pharmaphorum

MARCH 1, 2022

This was, and still is being, demonstrated through the UK’s COVID-19 vaccine research successes. She began her career in clinical research as a clinical trial assistant for Novartis Vaccines and Diagnostics in 2007 and continued to pursue her interest is vaccine research in 2014 when she joined GSK (formerly Novartis Vaccines).

Vaccines 96

Vaccines Hospitals 96

pharmaphorum

NOVEMBER 16, 2020

In his final message as head of the EMA, Rasi said the number of COVID-19 drugs and vaccines being developed by pharma companies is “encouraging,” and pointing to the agency’s pivotal role “in reviewing the available data packages to ensure that our usual high standards of safety, efficacy and quality are achieved and upheld.”.

Vaccines 64

Vaccines Packaging FDA 64

PharmaShots

APRIL 13, 2023

and became a leader in the medical device industry Novartis raised its sales by 16% and acquired Alcon (ophthalmic business), Genoptix (oncology business), and an 85% stake in Zhejiang Tianyuan (vaccine business) Bayer recorded a revenue of $49B as its pharmaceutical business posted an encouraging performance in the emerging market.

Vaccines 40

Vaccines Pharmaceutical Companies Pharmaceutical Companies Labelling 40

pharmaphorum

APRIL 19, 2021

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. But Dix has also been leading the UK’s Vaccine Taskforce, after taking over the hot seat in December following the departure of Kate Bingham.

Vaccines 98

Vaccines 98

ISPE

AUGUST 29, 2022

Published July 2014. The rapid transition between clinical studies to emergency use authorization, and then to the world’s first fully approved vaccine in under two years, highlights the potential of biopharmaceutical companies and health authorities. Lo Surdo, J., Cauchon, C. Ramdas, and E. Zavialov. “A

Documentation 52

Documentation FDA Communication Packaging 52

ISPE

SEPTEMBER 11, 2023

Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. New Project: Evolutive Vaccines Facility for Sanofi.” www.boccard.com/evolutive-vaccines-facility-for-sanofi/ 42 Amgen.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

PharmaShots

JANUARY 31, 2023

The Company's premier line of smart safety syringes, Sharps Provensa, prevents accidental needlestick injuries, prevents needle reuse, and minimizes drug and vaccine waste—all while maintaining the intuitive simplicity of conventional syringes. Founded Year: 2014 No. Funding Value: $15.9M Founded Year: 2007 No. of Shares: 3.7M

Vaccines 40

Vaccines Immunization FDA 40

PharmExec

MARCH 13, 2024

Data shows that from 2014-2019, pneumococcal vaccinations in seniors increased by 10%, growing sales for Prevnar 13 due to government recommendation in addition to a high-profile advertising campaign.

Vaccines 52

Vaccines 52

pharmaphorum

DECEMBER 21, 2020

Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.

Vaccines 111

Vaccines Immunization 111

STAT

JANUARY 11, 2023

When I learned that an outbreak of Ebola was declared in Uganda last fall, I had a flashback to 2014 when I was working at Merck and an outbreak of Ebola disease caused by a different species of the virus emerged in full force in West Africa.

Vaccines 90

Vaccines 90

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Vaccines 52

Vaccines Immunization FDA 52

pharmaphorum

MAY 25, 2021

She went on to describe another study, EAVE II , which has drawn on BREATHE’s expertise, linking patient data across the entire Scottish population to provide the first real-world evidence of the success of the COVID-19 vaccination programme in cutting risk of hospital admission. About Savana.

Hospitals 104

Hospitals Vaccines 104

pharmaphorum

JUNE 10, 2021

The need for firms to make a reasonable profit is paramount in today’s world; healthy pharmaceutical research and manufacturing are the keys to ending disease, curing chronic conditions, and discovering new therapies and vaccines that address the latest medical challenges.

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies Vaccines Documentation 105

pharmaphorum

DECEMBER 2, 2020

In 2014 the company made an offer of around $100 billion to acquire UK firm AstraZeneca (which at the time was going through a rough patch ). The $12 billion deal was cleared in November 2020, creating a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word.

Compounding 128

Compounding Vaccines Pharmaceutical Companies Pharmaceutical Companies 128

Hospital Pharmacy Europe

MAY 9, 2024

In 2014 and 2015 Professor Claverie’s team revived a 30,000-year-old virus, leading to media attention about so-called ‘zombie viruses’. Over 70 graphics, including alternatives to handshakes and explanations of mRNA vaccines, were then created and published online by The Spinoff, a New Zealand news outlet.

Hospitals 52

Hospitals Communication Clinic Management Documentation 52